Windjammer Capital acquires monoclonal antibodies producer Bio X Cell
Windjammer Capital Investors (“Windjammer”), a notable private equity investment firm, has announced its acquisition of Bio X Cell, LLC (“BXC”), marking a significant move in the biotech industry. This acquisition, completed on November 6, represents Windjammer’s strategic investment in a leading producer of monoclonal antibodies, vital for pre-clinical research applications. Founded by Dr. Klaus Lubbe […]